Compare SER & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SER | CTSO |
|---|---|---|
| Founded | 2017 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.0M | 49.7M |
| IPO Year | 2018 | N/A |
| Metric | SER | CTSO |
|---|---|---|
| Price | $3.39 | $0.72 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $13.00 | $5.38 |
| AVG Volume (30 Days) | 17.2K | ★ 126.1K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $116,000.00 | ★ $36,979,520.00 |
| Revenue This Year | $134.46 | $9.51 |
| Revenue Next Year | N/A | $24.40 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 23.89 |
| 52 Week Low | $3.28 | $0.60 |
| 52 Week High | $7.92 | $1.61 |
| Indicator | SER | CTSO |
|---|---|---|
| Relative Strength Index (RSI) | 30.89 | 46.64 |
| Support Level | $3.68 | $0.70 |
| Resistance Level | $4.26 | $0.85 |
| Average True Range (ATR) | 0.26 | 0.07 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 1.94 | 52.04 |
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.